期刊文献+

雌激素受体不同表达对局部晚期乳腺癌TC化疗方案的敏感性观察 被引量:3

Association Between Different ER Expression and the Sensitivity of TC Chemotherapy in Locally Advanced Breast Cancer Patients
原文传递
导出
摘要 目的:观察雌激素受体(ER)不同表达对局部晚期乳腺癌TC新辅助化疗方案的敏感性。方法:采用免疫组化EnVision法,检测57例局部晚期乳腺癌患者化疗前ER的表达情况,比较ER(-)病例与ER(+)病例对TC化疗方案的敏感性。结果:ER阴性组的敏感性为86.36%(19/22),ER阳性组的敏感性为60.00%(21/35),2组比较差异有统计学意义(P<0.05),说明ER(-)的乳腺癌患者对TC新辅助化疗方案更敏感。结论:ER(-)可作为局部晚期乳腺癌选用TC新辅助化疗方案的敏感性依据之一。 OBJECTIVE: To observe the association between the ER expression and the sensitivity of TC chemotherapy in locally advanced breast cancer patients. METHODS: The expression of ER in 57 locally advanced breast cancer patients was detected by EnVision method, and the sensitivity to TC chemotherapy in ER negative ( - )vs. ER positive ( + ) patients were evaluated. RESULTS: There were significant differences between the ER negative ( - ) patients and the ER positive ( + ) patients in the sensitivity to TC chemotherapy(86.36% (19/22) vs. 60.00% (21/35) ) (P (0.05), demonstrating the higher sensitivity of ER negative( - ) breast cancer patients to TC neoadjuvant chemotherapy. CONCLUSION: ER negative ( - ) may serve as a sensitivity marker to TC neoadjuvant chemotherapy in locally advanced breast cancer patients.
出处 《中国药房》 CAS CSCD 北大核心 2009年第20期1558-1559,共2页 China Pharmacy
关键词 乳腺癌 新辅助化疗 疗效 雌激素受体 Breast cancer Neoadjuvant chemotherapy Efficacy Estrogen receptor
  • 相关文献

参考文献3

二级参考文献22

  • 1杨玲,李连弟,陈育德,Donald Maxwell Parkin.中国肺癌死亡趋势分析及发病、死亡的估计与预测[J].中国肺癌杂志,2005,8(4):274-278. 被引量:168
  • 2Greenlee RT,Hill-Harmon M,Murray T,et al.Cancer statistics[J].CA Cancer J Clin,2001,51:15.
  • 3Hainsworth JD,Burris HA,Erland JB,et al.Phase Ⅰ / Ⅱ trial of paclitaxel by 1-hour infusion,carboplatin,and gemcitabine in the treatment of patients with advanced non-small cell lung carcinoma[J].Cancer,1999,85(6):1 269.
  • 4Wasil T,Lichtman SM.Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drvgs in the elderly[J].Oncologist,2005,10(8):602.
  • 5Singla AK,Garg A,Aggarwal D,et al.Pacitaxel and its formulation[J].Lnt J Pharm,2002,235(12):179.
  • 6Fisher ER,Wang J,Bryant J,et al.Pathobiology of preoperative chemotherapy findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18[J].Cancer,2002,95:681-695.
  • 7Schneeweiss A,Katretchko J,Sinn HP,et al.Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy[J].Anticancer Drugs,2004,15(2):127-135.
  • 8Colleoni M,Minchella I,Mazzarol G,et al.Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptor[J].Ann Oncol,2000,11:1-3.
  • 9MacGrogan G,Mauriac L,Durand M,et al.Primary chemotherapy in breast invasive carcinoma:predictive value of the immuno-histochemical detection of hormonal receptors,p53,c-erbB-2,MiB1,pS2 and GST pi[J].Br J Cancer,1996,74:1458-1465.
  • 10Mieog JS,van der Hage JA,van de Vijuer MJ,et al.Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer:The predictive role of p53 expression[J].Eur J Cancer,2006,42(10):1369-1379.

共引文献10

同被引文献19

  • 1杨利娟,黄君梅,王飞.何首乌、骨碎补和淫羊藿的植物雌激素作用研究[J].中药与临床,2012,3(3):37-40. 被引量:42
  • 2叶魏武,王晓稼.三苯氧胺与乳腺癌防治研究进展[J].肿瘤研究与临床,2005,17(6):425-427. 被引量:3
  • 3Jacolot F,Simon I,Dreano I,et al. Identification of thecytochrome P45o ID a family as the enzymes involved in then-demethylation of tamoxifen in human liver micro- somes[J]. Biochem Pharmacol, 1991,41(12):1 911.
  • 4Mani C, Gelboin HV,Park SS,et al Metabolism of theantimammary cancer antiestrogenic agent tamoxifentamo-xifen. I . Cytochrome P45o-catalysed N-demethylation and4-hydroxylation[J]. Drug Metab Dispos,1993,21 (4):645.
  • 5Rao US, Fine RL,Scarborough GA. Antiestrogens and st-eroid hormones : substrates of the human P-glycoprotein[J]. Biochem Pharmacol,1994,48(2) :287.
  • 6Bode JC. Silymarin for the therapy of liver disease[J]. AJG ,1999,94(2):545.
  • 7Kroll DJ,Shaw HS,Oberlies NH. Milk thistle nomencla-ture :why it matters in cancer research and pharmacokinet-ic studies[J]. Integr Cancer 2007,6(2) : 110.
  • 8Kim CS,Choi SJ, Park CY,et al Effects of silybinin onthe pharmacokinetics of tamoxifen and its active metabo-lite ,4-hydroxytamoxifen in rats[J]. Anticancer Res, 2010 ,30(2):79.
  • 9Golander Y, Sterason LA. Paired-ion chromatographic an-alysis of tamoxifen and two major metabolites in Plasma[J], JChromatogr,1980,181(1):41.
  • 10王蓓,傅健飞,洪中武.新辅助化疗FEC方案和TEC方案对乳腺癌患者的疗效[J].癌症,2009,28(3):292-296. 被引量:13

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部